MicroRNA-155 promotes the pathogenesis of experimental colitis by repressing SHIP-1 expression

Figure 5 Inhibition of microRNA-155 alleviates colitis by regulating the SHIP-1/Akt signaling pathway. A: AntagomiR-155 treatment elevated the mRNA expression of SHIP-1. ^bP < 0.01, DSS vs control; ^aP < 0.05, DSS + antagomiR-155 vs DSS + NC; B: Western blot analysis of the protein levels of SHIP-1, Akt, and p-Akt after antagomiR-155 treatment, with normalized to GAPDH; C: Immunohistochemistry staining and semi-quantification for SHIP-1 in mice colon tissues. ^bP < 0.01, DSS vs control; ^aP < 0.05, DSS + antagomiR-155 vs DSS + NC. D: The mRNA expression levels of key factors involved in colitis-related inflammatory response. Comparison was conducted between groups: DSS, DSS + NC vs control; and DSS + antagomiR-155 vs DSS, DSS + NC. ^aP < 0.05, ^bP < 0.01. DSS: Dextran sulfate sodium.